VP of Research Products Dr Farah Patell-Socha discusses more accurate cell models in neurodegeneration.
VP of Research Products Dr Farah Patell-Socha discusses more accurate cell models in neurodegeneration.
VP of Research Products Dr Farah Patell-Socha discusses more accurate cell models in neurodegeneration.
VP of Research Products Dr Farah Patell-Socha discusses more accurate cell models in neurodegeneration.
CEO Mark Kotter gives an evening lecture at the famous Royal Institution on the cell reprogramming revolution.
bit.bio expands senior team with four female hires in further preparation for cell therapies.
The award was presented at evening ceremony in central London.
The posters demonstrate the capability of opti-ox technology to create any human cell.
bit.bio and Charles River Laboratories discuss the potential of precision reprogrammed human cells.
The piece talks about how bit.bio has "cracked the code" to grow human cells for a new era of regenerative medicine.
bit.bio wins biotech of the year for the second time and CEO of the year for Mark Kotter.
The new Huntington’s disease human cell model is built with opti-ox reprogrammed glutamatergic neurons.